Biopharmaceuticals & Biomedicine Market Report: Segmentation By Branch, Implications, Application, & Region, Overview(Emerging Trends, Risk analysis, Y-O-Y Growth Rate, Opportunities Assessment, Statistics, Scope, Share, Demand, Competitor Analysis)

Biopharmaceuticals & Biomedicine Market in the Global Industry Landscape

Biopharmaceuticals & biomedicine deals with the research and development of drugs (biologics) partially or completely using biological compounds. The year 2017 has witnessed huge growth in biopharmaceutical industry. Biomedicines are increasingly penetrating the market as the drug manufacturers and other pharmaceutical companies are inclining towards R&D of biomedicine. Thus continuous R&D, approval and huge pipeline of biomedicine and biopharmaceutical products are driving the growth of the industry. In 2017, US FDA has approved 56 new medicines, which is highest in past 2 decades. Oncology biopharmaceutical is one the most attractive segment, ensuring better treatment to the cancer and tumor patients. Although the prices of biomedicine are higher than branded medicines but effectiveness and quick response of biomedicine is keeping up the demand and over the forecast period (2017-2025) it is anticipated to have larger market share of the pharmaceutical industry.

Our Global Biopharmaceutical & Biomedicine Market can be segmented on the following basis:

Based on Biopharmaceuticals & Biomedicine Branch

• Cell Technologies
• Nano Medicine
• Gene Therapy
• Bio Chips
• System Biology
• Bio Informatics

Based on Implications

• Oncology
• Neuroscience
• Infectious Disease
• Immunology
• Hematology
• Hemophilia
• Ophthalmology
• Respiratory

Based on Application

• Therapeutics
• Diagnostics
• Research & Development

Based on Geography

• North America (U.S. & Canada)  Biopharmaceuticals & Biomedicine Market {Market Share (%), Market Size (USD Billion)}
• Latin America (Brazil, Mexico, Argentina & Rest Of Latin America)  Biopharmaceuticals & Biomedicine Market {Market Share (%), Market Size (USD Billion)}
• Europe (The U.K., Germany, France, Italy, Hungary, Spain, Poland, Sweden & Roe)  Biopharmaceuticals & Biomedicine Market {Market Share (%), Market Size (USD Billion)}
• Asia-Pacific (China, India, Japan, Singapore, South Korea, Australia, New Zealand, Rest Of Asia)  Biopharmaceuticals & Biomedicine Market {Market Share (%), Market Size (USD Billion)}
• Middle East & Africa (GCC, South Africa, North Africa, Romea) Biopharmaceuticals & Biomedicine Market {Market Share (%), Market Size (USD Billion)}

Global Biopharmaceutical & Biomedicine Market Outlook comprises of the following data:

• Biopharmaceutical & biomedicine market size and market compounded annual growth rate, 2017-2025
• Marketed biomedicine sales and revenue, by region, 2017-18
• Pharmaceutical products demand analysis, 2017-2025
• Biomedicine approval scenario, 2017-18
• Biomedicines in pipeline, 2017-18
• Number of Oncology cases and growth rate of oncology cases, 2017-18
• Biopharmaceutical industry competitor’s outlook.

Key Players Mentioned In the Report

Amgen, Merck Serono, Roche, Biogen, Inc., Gilead Sciences, Inc., Genzyme, MedImmune, Celltech Group plc, Boehringer Ingelheim, Novartis, Biocon, AbbVie, Teva and many more.

Asia Pacific Biopharmaceutical & Biomedicine Industry: Investments in Asia Pacific region is a new trend in the biopharmaceutical industry. China Food and Drug Administration (CFDA) is expected to be flooded with the approval and launch of new products. The CFDA is witnessed in past 3 years to come up with reforms in the industry. Moreover, Japan Ministry of Health, Labor and Welfare (MHLW) has also made price reforms impacting the in-market drugs price revision and also the new drugs. Similarly, South Asia biopharmaceutical industry is also witnessing high growth waves.

Competition Analysis: Biopharmaceutical & biomedicine have changed the landscape of competition in the pharmaceutical industry. The branded drug manufacturers and pharmaceuticals as seen till now were in competition with the generic drug manufacturers. Whereas, now the branded drug manufacturers are likely to shift their interest towards biopharmaceutical products. Moreover, even the low profit margin in the manufacturing and marketing of biopharmaceutical products & biomedicine, the companies are witnessed to incline towards them owing to the future growth prospects of the biopharmaceutical industry.